Related Experiment Video
Updated: Dec 30, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Pluronic Polymer-Based Ormeloxifene Nanoformulations Induce Superior Anticancer Effects in Pancreatic Cancer Cells
Neeraj Chauhan1,2,3, Amber Kruse3,4, Hilary Newby3,5
1Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, United States.
Abstract:
Utilization of safe cytotoxic agents with precise anticancer activity is considered as the prime focus of cancer therapeutics research. A greater incentive for such agents arises from the molecules/drugs that are already being used for other indications. Ormeloxifene (ORM) is a nonsteroidal, nonhormonal selective estrogen receptor modulator (SERM), which has been in human use for contraception purposes. Although in the recent past, many reports have suggested its emerging role as an anticancer agent, no significant attention was paid toward generating simple and safe nanoformulation(s) for improved therapeutic activity and tumor cell-specific delivery. Our aim is to develop nanoformulation(s) of ormeloxifene to improve its targeted delivery in tumor cells. We developed ormeloxifene nanoformulation(s) by utilizing various biocompatible polymers. The optimized formulations with pluronic polymers F127 and F68 show improved nanoparticle characteristics. These formulations show enhanced cellular uptake that allows ormeloxifene's intracellular availability. We further evaluated its improved anticancer activity by performing cell proliferation, flow cytometry, and immunoblotting assays. Overall, this study confirms possible novel nanoformulation(s) of ormeloxifene to be evolved as a new therapeutic modality for cancer treatment.
Insights
Researchers developed novel nanoformulations of ormeloxifene (ORM), a selective estrogen receptor modulator (SERM), to enhance its anticancer activity and tumor cell targeting. These safe and effective nanoformulations show improved cellular uptake for potential cancer treatment.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- The development of safe cytotoxic agents with precise anticancer activity is a key focus in cancer research.
- Ormeloxifene (ORM), a selective estrogen receptor modulator (SERM) used for contraception, has shown potential as an anticancer agent.
- Existing research lacks targeted nanoformulations for ORM to improve its therapeutic efficacy and delivery to tumor cells.
Purpose of the Study:
- To develop and characterize novel nanoformulations of ormeloxifene (ORM) for enhanced cancer therapy.
- To improve the targeted delivery and intracellular availability of ORM in tumor cells.
- To evaluate the anticancer potential of ORM nanoformulations.
Main Methods:
- Development of ormeloxifene nanoformulations using biocompatible polymers, including pluronic F127 and F68.
- Characterization of nanoparticle properties and assessment of cellular uptake.
- Evaluation of anticancer activity through cell proliferation assays, flow cytometry, and immunoblotting.
Main Results:
- Optimized nanoformulations exhibited improved nanoparticle characteristics.
- Enhanced cellular uptake and intracellular availability of ormeloxifene were observed.
- The nanoformulations demonstrated significant anticancer activity in vitro.
Conclusions:
- Novel nanoformulations of ormeloxifene (ORM) were successfully developed, showing enhanced properties for cancer treatment.
- These nanoformulations facilitate targeted delivery and improved intracellular availability of ORM.
- Ormeloxifene nanoformulations represent a promising new therapeutic strategy for cancer treatment.
